NASDAQ:CGEN - Compugen Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.64 -0.16 (-4.21 %)
(As of 10/19/2018 04:00 PM ET)
Previous Close$3.80
Today's Range$3.61 - $3.79
52-Week Range$2.25 - $5.00
Volume119,600 shs
Average Volume246,262 shs
Market Capitalization$187.73 million
P/E Ratio-5.07
Dividend YieldN/A
Beta1.11
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Its product pipeline consists of COM701, a monoclonal antibody designed to block the interaction of PVRIG with its cognate ligand, PVRL2; CGEN-15001T, an immuno-oncology therapeutic program for ILDR2; and COM902, a therapeutic antibody candidate for its TIGIT program. The company's pipeline also comprises therapeutic proteins include CGEN-15001, a fusion protein drug candidate for autoimmune diseases, including extracellular domain of ILDR2 and an IgG Fc domain. Compugen Ltd. has a clinical trial collaboration with Bristol-Myers Squibb Company to evaluate the safety of COM701 in combination with Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. The company was incorporated in 1993 and is headquartered in Holon, Israel.

Receive CGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CGEN
CUSIPN/A
Phone972-3765-8585

Debt

Debt-to-Equity RatioN/A
Current Ratio5.92
Quick Ratio5.92

Price-To-Earnings

Trailing P/E Ratio-5.07
Forward P/E Ratio-8.67
P/E GrowthN/A

Sales & Book Value

Annual Sales$710,000.00
Price / Sales262.95
Cash FlowN/A
Price / CashN/A
Book Value$0.57 per share
Price / Book6.39

Profitability

EPS (Most Recent Fiscal Year)($0.72)
Net Income$-37,060,000.00
Net MarginsN/A
Return on Equity-84.71%
Return on Assets-66.55%

Miscellaneous

Employees101
Outstanding Shares51,290,000
Market Cap$187.73 million

Compugen (NASDAQ:CGEN) Frequently Asked Questions

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) announced its quarterly earnings results on Wednesday, August, 1st. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.19). View Compugen's Earnings History.

When is Compugen's next earnings date?

Compugen is scheduled to release their next quarterly earnings announcement on Tuesday, November 6th 2018. View Earnings Estimates for Compugen.

What price target have analysts set for CGEN?

2 brokerages have issued 12-month price targets for Compugen's shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate Compugen's share price to reach $9.00 in the next year. This suggests a possible upside of 147.3% from the stock's current price. View Analyst Price Targets for Compugen.

What is the consensus analysts' recommendation for Compugen?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Compugen.

Who are some of Compugen's key competitors?

Who are Compugen's key executives?

Compugen's management team includes the folowing people:
  • Dr. Anat Cohen-Dayag, Chief Exec. Officer, Pres and Director (Age 51)
  • Mr. Ari Krashin, Chief Financial and Operating Officer (Age 45)
  • Mr. Kirk A. Christoffersen MBA, Sr. VP of Corp. and Bus. Devel. (Age 49)
  • Dr. Zurit Levine Ph.D., VP of Research & Discovery (Age 50)
  • Dr. John J. Hunter, VP of Antibody R&D (Age 55)

Who are Compugen's major shareholders?

Compugen's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Taylor Frigon Capital Management LLC (1.15%).

Which institutional investors are selling Compugen stock?

CGEN stock was sold by a variety of institutional investors in the last quarter, including Taylor Frigon Capital Management LLC.

How do I buy shares of Compugen?

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Compugen's stock price today?

One share of CGEN stock can currently be purchased for approximately $3.64.

How big of a company is Compugen?

Compugen has a market capitalization of $187.73 million and generates $710,000.00 in revenue each year. The biotechnology company earns $-37,060,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Compugen employs 101 workers across the globe.

What is Compugen's official website?

The official website for Compugen is http://www.cgen.com.

How can I contact Compugen?

Compugen's mailing address is AZRIELI CENTER 26 HAROKMIM STREET BUILDING D, HOLON L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]


MarketBeat Community Rating for Compugen (NASDAQ CGEN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  210 (Vote Outperform)
Underperform Votes:  191 (Vote Underperform)
Total Votes:  401
MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe CGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2018 by MarketBeat.com Staff

Featured Article: Stock Split

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel